Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06765681 · ClinicalTrials.gov registry record

An Observational Study in the United States to Learn How Venous Thromboembolism, Disseminated Intravascular Coagulation, and Sepsis Are Related

A clinical trial of Sepsis and Venous Thromboembolism, sponsored by Bayer.

Active
Registry status
10,000
Enrollment target
1
Study location

NCT06765681 is a study of Sepsis and Venous Thromboembolism that is active but no longer recruiting, run by Bayer. The registered enrollment target is 10,000 participants, above the 6,454-participant average among 90 other Sepsis trials with a reported enrollment target (55% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06765681, a study of Sepsis and Venous Thromboembolism, is active but no longer recruiting, sponsored by Bayer.

ACTIVE NOT RECRUITING
Registry status
10,000 participants
Enrollment target
1
Study location

Study Summary

This is an observational study in which data already collected from people with venous thromboembolism (VTE) due to sepsis (blood poisoning) are studied. These people were hospitalized in an intensive care unit (ICU) and may or may not have had disseminated intravascular coagulation (DIC). In this observational study, only observations are made without participants receiving any advice or changes to their healthcare. VTE is a condition that occurs when blood clots form in the veins, which can be dangerous. DIC is a serious blood disorder that can cause clots throughout the body, blocking blood flow. People who have sepsis are at a higher risk of developing both VTE and DIC. Researchers wanted to know if people who have sepsis developed DIC before developing VTE. To prevent VTE in people with sepsis, it is important to know how severe the sepsis is, how it progresses, and whether DIC is also present or not. In this study, researchers will assess patient data from a medical database in the United States (US). The main purpose of this study is to learn if there is a relationship between sepsis, DIC, and VTE. To do this, researchers will divide the participants with VTE due to sepsis into three groups as follows: * participants who were diagnosed with DIC based on the extent of blood clotting * participants who likely had DIC but it was not diagnosed * participants who did not develop DIC during the same hospital visit The researchers will collect the following information: * the number of participants who had VTE due to sepsis also had DIC * the change in participants' laboratory results and vital signs, such as heart rate and blood pressure, from the time their sepsis was diagnosed to the time their VTE and DIC were diagnosed The researchers will study the data collected between January 2007 and December 2021. The data will come from the participants' information stored in a database called the Optum VTE EHR which collects patient medical data from hospital

Interventions

  • OTHER Diagnosis of both VTE and sepsis

Study Locations (1)

New Jersey

  • Bayer - Whippany

Trial Details

FieldValue
Enrollment Target 10,000 participants
Start Date 2025-01-06
Est. Completion 2026-03-31

Sponsor

Bayer

591 total trials

What the Registry Record Tells You About NCT06765681

The ClinicalTrials.gov registry entry for NCT06765681 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 10,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 6,454-participant average among 90 other Sepsis trials with a reported enrollment target (55% higher). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which Diagnosis of both VTE and sepsis is the first listed.

NCT06765681 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT06765681 about?

NCT06765681 is a clinical study titled "An Observational Study in the United States to Learn How Venous Thromboembolism, Disseminated Intravascular Coagulation, and Sepsis Are Related". This is an observational study in which data already collected from people with venous thromboembolism (VTE) due to sepsis (blood poisoning) are studied. These people were hospitalized in an intensive care unit (ICU) and may or may not have had disseminated intravascular coagulation (DIC). In this ...

What is the current status of trial NCT06765681?

This trial is currently active not recruiting. The enrollment target is 10,000 participants. The study started on 2025-01-06. Estimated completion is 2026-03-31.

What conditions does trial NCT06765681 study?

This clinical trial studies the following conditions: Sepsis, Venous Thromboembolism, Disseminated Intravascular Coagulation.

What interventions are being tested in trial NCT06765681?

The interventions under investigation include: Diagnosis of both VTE and sepsis (OTHER).

Who is sponsoring clinical trial NCT06765681?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06765681 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sepsis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.